• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Peptic Ulcers - Pipeline Review, H2 2012 Product Image

Peptic Ulcers - Pipeline Review, H2 2012

  • ID: 2298910
  • October 2012
  • 79 pages
  • Global Markets Direct

Peptic Ulcers – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Peptic Ulcers - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Peptic Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peptic Ulcers. Peptic Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Peptic Ulcers.
- A review of the Peptic Ulcers products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Peptic Ulcers Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Peptic Ulcers 9
Peptic Ulcers Therapeutics under Development by Companies 11
Peptic Ulcers Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Peptic Ulcers Therapeutics – Products under Development by Companies 18
Peptic Ulcers Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Peptic Ulcers Therapeutics Development 20
Sequella, Inc. 20
AstraZeneca PLC 21
Takeda Pharmaceutical Company Limited 22
Daewoong Pharmaceutical Co., Ltd. 23
Eisai Co., Ltd. 24
PLx Pharma Inc. 25
aRigen Pharmaceuticals, Inc. 26
Logical Therapeutics, Inc. 27
China Medical System Holdings Limited 28
Vecta Ltd. 29
Medigreen Biotechnology Corporation 30
HeliCure AB 31
Peptic Ulcers – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
TAK-438 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
IMD-4 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DWJ-206 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rabeprazole sodium - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
esomeprazole magnesium - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SQ-109 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ARH-1029 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vecam - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Duexis - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
naproxen - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
naproxen - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
aspirin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 55
Axanum - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rabeprazole sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
esomeprazole magnesium - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CMSH-001 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
lansoprazole - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HZN-602 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MIC-31 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Helicobacter Pylori Vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Peptic Ulcers Therapeutics – Drug Profile Updates 64
Peptic Ulcers Therapeutics – Discontinued Products 70
Peptic Ulcers Therapeutics - Dormant Products 71
Peptic Ulcers – Product Development Milestones 72
Featured News & Press Releases 72
Sep 28, 2012: Horizon Pharma Receives Two Additional US Patent Allowances For Duexis 72
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 72
Aug 23, 2012: Pozen Provides Update On Low Dose Gastric Ulcer Drug 73
Aug 23, 2012: Pozen Provides Update On PA Program And Results Of Type A Meeting With FDA 73
Jun 22, 2012: AstraZeneca Receives Approval For Nexium In Japan For Prevention Of Recurrence Of Gastric ulcer And Duodenal Ulcer 74
Jun 22, 2012: AstraZeneca Receives Approval For Nexium In Japan For Prevention Of Recurrence Of Gastric ulcer And Duodenal Ulcer 75
Jun 20, 2012: Pozen Announces FDA Response To Phase I Bioequivalence Study Analyses Of PA32540 75
May 20, 2012: Sucampo Presents Preclinical Data Of Cobiprostone At Digestive Disease Week 2012 76
May 19, 2012: Pozen Presents Phase I Data Of PA32540 At Digestive Disease Week 2012 76
Mar 29, 2012: Covis's Zantac Injection Returns To Market 77
Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

List of Tables
Number of Products Under Development for Peptic Ulcers, H2 2012 9
Products under Development for Peptic Ulcers – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sequella, Inc., H2 2012 20
AstraZeneca PLC, H2 2012 21
Takeda Pharmaceutical Company Limited, H2 2012 22
Daewoong Pharmaceutical Co., Ltd., H2 2012 23
Eisai Co., Ltd., H2 2012 24
PLx Pharma Inc., H2 2012 25
aRigen Pharmaceuticals, Inc., H2 2012 26
Logical Therapeutics, Inc., H2 2012 27
China Medical System Holdings Limited, H2 2012 28
Vecta Ltd., H2 2012 29
Medigreen Biotechnology Corporation, H2 2012 30
HeliCure AB, H2 2012 31
Assessment by Monotherapy Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Peptic Ulcers Therapeutics – Drug Profile Updates 64
Peptic Ulcers Therapeutics – Discontinued Products 70
Peptic Ulcers Therapeutics – Dormant Products 71

List of Figures
Number of Products under Development for Peptic Ulcers, H2 2012 9
Products under Development for Peptic Ulcers – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos